Program
TRK/RET Inhibitor ND-003
Also written as “ND-003 tablets”, “ND-003 Tablets” and “ND-003 40mg”.
Its studies are mostly in Idiopathic Pulmonary Fibrosis, led by Shenzhen NewDEL Biotech.
Furthest: phase 2, since Oct 25, 20263 company-led studies, 3 open or runningNext primary completion: Jun 2028 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Shenzhen NewDEL Biotech | 33 open or running | phase 2since Oct 25, 2026 | Nov 23, 2023 | Jun 2028phase 1 · NCT06169579 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 23, 2023First study: phase 1 study in Advanced Solid TumorFirst studyNCT06169579 · 96 planned · China
- Mar 28, 2024Phase 1 study in HealthyNCT06360874 · 104 planned · China
- Oct 25, 2026Phase 2 study in Idiopathic Pulmonary FibrosisPhase 2 reachedNCT07929948 · 10 planned · China
Ahead
- Jun 2028Primary completion: phase 1 study in Advanced Solid TumorNCT06169579
- Jun 30, 2028Primary completion: phase 2 study in Idiopathic Pulmonary FibrosisNCT07929948
TargetBeta
RET →read by rule
“An orally bioavailable small molecule inhibitor of multiple kinases, including tropomyosin-related-kinase (TRK) and rearranged during transfection (RET), ”NCIt, by rule
Other programs on RET
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| regorafenibrule | Bayer | phase 4 | 40 |
| selpercatinibrule | Eli Lilly | phase 4 | 19 |
| pralsetinibrule | Hoffmann-La Roche | phase 4 | 7 |
| quizartinibrule | Daiichi Sankyo | phase 3 | 22 |
| RET Inhibitor HS-10365 | Hansoh Pharmaceutical Group | phase 2 | 3 |
| RET Inhibitor FHND5071 | Sino Biopharmaceutical | phase 1 | 1 |
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07929948Idiopathic Pulmonary Fibrosis · China | 2 | By invitation | Jun 30, 2028 | 10 |
| NCT06360874Healthy · China | 1 | By invitation | Dec 2024 | 104 |
| NCT06169579Advanced Solid Tumor · China | 1 | By invitation | Jun 2028 | 96 |
How it is read
Names in the registry
- “ND-003 tablets”, 8 entries
- “ND-003 Tablets”, 1 entry
- “ND-003 40mg”, 1 entry
- “ND-003 80mg”, 1 entry
- “ND-003 160mg”, 1 entry
Conditions, from the studies’ own filings
- Idiopathic Pulmonary Fibrosis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.